<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107819</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-16-1078</org_study_id>
    <nct_id>NCT03107819</nct_id>
  </id_info>
  <brief_title>Metabolomics for Biomarker Discovery in Children With EoE</brief_title>
  <official_title>Plasma and Urine Metabolomics for Biomarker Discovery in Children With Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are seeking to enroll 8 children ages 2-18 already undergoing upper
      endoscopy. For the purposes of research, a peripheral blood and clean catch urine specimen
      will be obtained to measure plasma and urine metabolomics. The data will be used to determine
      if there are any key differences in the metabolite profile of subjects found to have
      eosinophilic esophagitis (EoE) versus non-EoE subjects. Once these metabolites are
      identified, the investigators will seek to enroll many more subjects for a validation phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eosinophilic esophagitis (EoE) is a disorder of the esophagus triggered by food and/or
      environmental allergens and is characterized by symptoms of esophageal dysfunction and
      eosinophilia of the esophagus. The standard of care for diagnosing and monitoring EoE is with
      biopsies of the esophagus. There are currently no known biomarkers that correlate with the
      inflammatory activity of esophageal mucosa, and patients' symptoms alone are insufficient in
      providing a reliable assessment. Some studies report that patients with EoE may undergo
      endoscopy up to 11 times in one year. Finding a non-invasive biomarker would therefore be of
      high clinical and economic interest.

      The investigators will seek to enroll 8 children ages 2-18 years already undergoing
      esophagogastroduodenoscopy (EGD). For the purposes of research, a peripheral blood specimen
      will be collected at the same time of peripheral intravenous (IV) placement, which is
      routinely performed for the purposes of sedation during endoscopy, thereby avoiding extra
      needle sticks. A urine sample will also be collected on the day of the EGD. These specimens
      will then be analyzed for plasma and urine metabolomics to evaluate for any derangements in
      EoE versus non-EoE subjects.

      Risks to participants undergoing EGD are the same as they would be if they were not enrolled
      in the study as no additional biopsies will be taken. Risks associated with a blood draw are
      minimal and include some discomfort, such as lightheadedness, fainting, bruising, soreness,
      clotting and bleeding at the site of the needle stick, and in rare cases, infection.
      Collection of the urine specimen is by clean catch in only toilet-trained individuals.

      This study should yield valuable information regarding plasma and urine metabolomics in EoE
      versus non-EoE subjects. Once this &quot;discovery&quot; data set is analyzed, future research could
      then focus specifically on those abnormal metabolites and seek to enroll many more subjects
      for a validation phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Actual">March 31, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma and urine metabolomics</measure>
    <time_frame>baseline</time_frame>
    <description>parts per million</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Pediatric patients undergoing EGD</arm_group_label>
    <description>Subjects ages 2-18 years undergoing upper endoscopy (EGD) will submit a blood and urine specimen for plasma and urine metabolomics profiling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Plasma and urine metabolomics</intervention_name>
    <description>Through the use of high-pressure liquid chromatography and mass spectrometry, quantitative measurements of targeted metabolites associated with amino acids, methylation, acetylation and the tricarboxylic acid (TCA) cycle will be analyzed on the blood and urine specimens.</description>
    <arm_group_label>Pediatric patients undergoing EGD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral venous blood, urine, esophageal mucosa biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children ages 2-18 years already undergoing upper endoscopy (EGD)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pediatric patients, ages 2-18 years, undergoing EGD with biopsies of the esophagus.

          2. Children with known EoE will only be enrolled if his/her biopsy on the day of specimen
             collection demonstrates ≥15 eosinophils (eos) per high power field (hpf).

        Exclusion Criteria:

          1. Presence of other disorders associated with similar clinical, histological or
             endoscopic features, such as proton pump inhibitor (PPI)-responsive esophageal
             eosinophilia, esophageal eosinophilia associated with gastroesophageal reflux, Crohn's
             disease, infectious esophagitis (i.e. herpes simplex virus or candida),
             drug-associated esophagitis, collagen vascular disease, hypereosinophilic syndrome and
             eosinophilic gastroenteritis.

          2. Children with known EoE and biopsy demonstrating &lt;15 eos/hpf at the time of specimen
             collection.

          3. Inability to provide a clean catch urine specimen (i.e. not toilet-trained).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon M Rhoads, MD</last_name>
    <role>Study Director</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassall E, Straumann A, Rothenberg ME; First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007 Oct;133(4):1342-63. Epub 2007 Aug 8. Review.</citation>
    <PMID>17919504</PMID>
  </reference>
  <reference>
    <citation>Gupta SK. Noninvasive markers of eosinophilic esophagitis. Gastrointest Endosc Clin N Am. 2008 Jan;18(1):157-67; xi. Review.</citation>
    <PMID>18061109</PMID>
  </reference>
  <reference>
    <citation>Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA; American College of Gastroenterology. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013 May;108(5):679-92; quiz 693. doi: 10.1038/ajg.2013.71. Epub 2013 Apr 9.</citation>
    <PMID>23567357</PMID>
  </reference>
  <reference>
    <citation>Cianferoni A, Spergel JM. Immunotherapeutic approaches for the treatment of eosinophilic esophagitis. Immunotherapy. 2014;6(3):321-31. doi: 10.2217/imt.14.3. Review.</citation>
    <PMID>24762076</PMID>
  </reference>
  <reference>
    <citation>Schlag C, Miehlke S, Heiseke A, Brockow K, Krug A, von Arnim U, Straumann A, Vieth M, Bussmann C, Mueller R, Greinwald R, Bajbouj M. Peripheral blood eosinophils and other non-invasive biomarkers can monitor treatment response in eosinophilic oesophagitis. Aliment Pharmacol Ther. 2015 Nov;42(9):1122-30. doi: 10.1111/apt.13386. Epub 2015 Aug 27.</citation>
    <PMID>26314389</PMID>
  </reference>
  <reference>
    <citation>Kagalwalla AF, Shah A, Li BU, Sentongo TA, Ritz S, Manuel-Rubio M, Jacques K, Wang D, Melin-Aldana H, Nelson SP. Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):145-9. doi: 10.1097/MPG.0b013e31821cf503.</citation>
    <PMID>21788754</PMID>
  </reference>
  <reference>
    <citation>Molina-Infante J, Arias A, Barrio J, Rodríguez-Sánchez J, Sanchez-Cazalilla M, Lucendo AJ. Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study. J Allergy Clin Immunol. 2014 Nov;134(5):1093-9.e1. doi: 10.1016/j.jaci.2014.07.023. Epub 2014 Aug 28.</citation>
    <PMID>25174868</PMID>
  </reference>
  <reference>
    <citation>Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):263-9. doi: 10.1038/nrm3314. Review.</citation>
    <PMID>22436749</PMID>
  </reference>
  <reference>
    <citation>Collino S, Martin FP, Rezzi S. Clinical metabolomics paves the way towards future healthcare strategies. Br J Clin Pharmacol. 2013 Mar;75(3):619-29. doi: 10.1111/j.1365-2125.2012.04216.x. Review.</citation>
    <PMID>22348240</PMID>
  </reference>
  <reference>
    <citation>Zhang A, Sun H, Wang P, Han Y, Wang X. Modern analytical techniques in metabolomics analysis. Analyst. 2012 Jan 21;137(2):293-300. doi: 10.1039/c1an15605e. Epub 2011 Nov 21. Review.</citation>
    <PMID>22102985</PMID>
  </reference>
  <reference>
    <citation>Sarosiek I, Schicho R, Blandon P, Bashashati M. Urinary metabolites as noninvasive biomarkers of gastrointestinal diseases: A clinical review. World J Gastrointest Oncol. 2016 May 15;8(5):459-65. doi: 10.4251/wjgo.v8.i5.459. Review.</citation>
    <PMID>27190585</PMID>
  </reference>
  <reference>
    <citation>Stephens NS, Siffledeen J, Su X, Murdoch TB, Fedorak RN, Slupsky CM. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J Crohns Colitis. 2013 Mar;7(2):e42-8. doi: 10.1016/j.crohns.2012.04.019. Epub 2012 May 22.</citation>
    <PMID>22626506</PMID>
  </reference>
  <reference>
    <citation>Davis VW, Schiller DE, Eurich D, Sawyer MB. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus. World J Surg Oncol. 2012 Dec 15;10:271. doi: 10.1186/1477-7819-10-271.</citation>
    <PMID>23241138</PMID>
  </reference>
  <reference>
    <citation>Jung J, Jung Y, Bang EJ, Cho SI, Jang YJ, Kwak JM, Ryu DH, Park S, Hwang GS. Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using NMR-based metabolomic profiling. Ann Surg Oncol. 2014 Dec;21 Suppl 4:S736-42. doi: 10.1245/s10434-014-3886-0. Epub 2014 Aug 5.</citation>
    <PMID>25092158</PMID>
  </reference>
  <reference>
    <citation>Qiu Y, Cai G, Su M, Chen T, Liu Y, Xu Y, Ni Y, Zhao A, Cai S, Xu LX, Jia W. Urinary metabonomic study on colorectal cancer. J Proteome Res. 2010 Mar 5;9(3):1627-34. doi: 10.1021/pr901081y.</citation>
    <PMID>20121166</PMID>
  </reference>
  <reference>
    <citation>Bertini I, Calabrò A, De Carli V, Luchinat C, Nepi S, Porfirio B, Renzi D, Saccenti E, Tenori L. The metabonomic signature of celiac disease. J Proteome Res. 2009 Jan;8(1):170-7. doi: 10.1021/pr800548z.</citation>
    <PMID>19072164</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Lindsay Marie Moye</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Plasma metabolomics</keyword>
  <keyword>Urinary metabolomics</keyword>
  <keyword>Metabonomics</keyword>
  <keyword>Biomarker discovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

